Most oxygen disasters across India could have been avoided. This blog describes the current model of medical oxygen supply in India, outlines the response to the oxygen crises, including the problem of severe oxygen shortages in some Indian states, and provides recommendations on how India could prevent the next crisis stemming from shortages in oxygen.
CGD Policy Blogs
Dear President Biden and Congress: Time for US to Lead Response to the Growing COVID-19 Global Vaccine Crisis
Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and safe vaccines, support rapid vaccine distribution and administration, and build a sustainable global network of vaccine manufacturing capacity. Vaccines offer an exit route out of the pandemic – but only if they reach a critical mass of people in need across continents, socioeconomic strata, and marginalized populations.
Expanding Health Product Manufacturing in Africa: Ideas for Development Finance Institutions, Procurers, and Policymakers
In October 2020, the Center for Global Development—in partnership with African Union Development Agency-NEPAD (AUDA-NEPAD), UN Economic Commission for Africa (UNECA), and the African Leaders Malaria Alliance—hosted a high-level roundtable on regional health product manufacturing in Africa. This blog is based on the authors’ reflections of the roundtable.
Today we launch an interactive tool that analyses the COVID-19 vaccine portfolio, and generates estimates about the timelines for the vaccines in the portfolio.
Making the $12 Billion Go Further: Four Things the World Bank Can Do in Support of COVID-19 Vaccination Efforts
To maximise the impact of this badly needed investment to combat COVID and, most importantly, to avoid any perverse and potentially catastrophic implications of World Bank financing undermining current global efforts led by Gavi and CEPI, we propose that the World Bank commit to the four principles below.
Our new paper aims to answer this question using mathematical modelling and expert interviews to: better understand the COVID-19 vaccine portfolio, and generate probabilistic estimates on timelines for approval and the manufacturing scale up.
We are developing a system of interconnected models which represent global manufacturing capability from the start of clinical trials to secondary vaccine manufacture; that is, time from first human trials to finished product ready to be shipped.
COVID-19 Surfaces New Directions for Old Challenges: Three Lasting Ways to Improve Global Health Procurement
Effective and efficient procurement of health products—medicines, diagnostics, and devices—is a critical function of all strong health systems. The pandemic has exacerbated long-standing challenges—as highlighted by a recent CGD Working Group—in the purchasing of both COVID-related emergency supplies and other essential health products.
Around the world COVID-19 and the policy responses to it are causing unprecedented disruptions of life and wellbeing. As scientists and governments around the world race to develop a vaccine at scale, we take a look at what a portfolio approach entails and why it is so important.
Maintaining Essential Services in the Time of COVID-19: Vaccination Delivery in Low- and Middle-Income Countries
As we observe World Immunisation Week, the implications of COVID-19’s spread for routine childhood vaccination delivery are already becoming clear.